Primary small cell neuroendocrine carcinoma of the right posterior tongue

Table 1 Clinical characteristics of the primary small cell neuroendocrine carcinomas in the oral cavity

Publication year	Age in yr	Sex	Smoking	Alcohol	Primary subsite	Disease stage	Therapy	RT dose in Gy	CM	Follow-up time in mo	RE	DM	Patient status1
1984	62	M	+	+	Tongue	IVA	S + RT + CM	Un	C+A+O	10	-	+	Died of DM
1995	76	M	+	+	Tongue	IVA	RT	72	-	2	-	-	Died of debility
2001	62	M	+	+	Mandible	IVA	-	-	-	3	-	+	Died of DM
2013	75	M	Un	Un	Tongue	III	S + RT	Un	-	Un	Un	Un	Un
2013	85	M	Un	Un	Cheek	III	CRT + S	40	CA	2.5	-	+	Died of DM
2013	59	M	Un	Un	Cheek	IVC	CM	Un	CI	16	-	+	Alive
2014	55	F	+	-	Tongue	IVA	S + CM	Un	Un	Un	-	-	Alive
2015	73	M	+	+	Lower gingiva	II	S + CM	-	CI + E	14	-	-	Alive
2015	54	M	Un	Un	Tongue	I	S + CM + RT	66	CI + E	Un	-	-	Alive
2015	40	F	Un	Un	Tongue	I	S + CM + CRT + CM	60	CI + E	52	-	-	Alive
2017	74	M	Un	Un	Tongue	IVC	CM	-	CA + E	9	-	-	Alive

¹As of publication. C + A + O: Cytoxan + Adriamycin + Oncovin; CA: Carboplatin; CA + E: Carboplatin + Etoposide; CI: Cisplatin; CI + E: Cisplatin + Etoposide; CM: Chemotherapy; CRT: Chemoradiotherapy; CT: Computerized tomography; DM: Distant metastasis; M: Male; F: Female; RE: Recurrence; RT: Radiotherapy; S: Surgery; Un: Unknown.